Precigen Inc. Reports Strong First‑Quarter 2026 Results Amid Rapid PAPZIMEOS Momentum
Precigen Inc. (Nasdaq: PGEN) released its first‑quarter 2026 financial results and business updates on May 13, 2026, highlighting a robust launch for its approved treatment PAPZIMEOS™ and a promising trajectory for its AdenoVerse® pipeline.
Financial Highlights
| Metric | Q1 2026 | YoY Change | Commentary |
|---|---|---|---|
| GAAP EPS | –$0.02 | Beat consensus by $0.02 | While Precigen remains unprofitable, the loss narrowed significantly compared with the prior‑year loss of –$0.18 per share. |
| Net Product Revenue | $21.6 M | Increase of $2.45 M | The revenue lift reflects a 145 % year‑over‑year surge in product sales, driven by PAPZIMEOS uptake. |
| Total Revenue | $23.25 M | $2.45 M higher than guidance | Precigen surpassed market expectations, reinforcing investor confidence. |
| Cash & Cash Equivalents | $56.7 M (as of March 31) | — | The cash position, combined with projected PAPZIMEOS revenue, is sufficient to achieve cash‑flow break‑even by the end of 2026. |
| Market Cap | $1.45 B | — | The company’s valuation remains robust in a highly competitive biopharma landscape. |
PAPZIMEOS™ – A Commercial Success Story
PAPZIMEOS™ is the first approved, non‑viral, non‑gene‑editing therapy for recurrent respiratory papillomatosis (RRP). In the first quarter of 2026, Precigen generated $21.6 million in net product revenue, a substantial increase from the $1.3 million recorded in the same period a year earlier. The growth is attributed to:
- Broad U.S. Market Penetration – The product’s “broad‑based uptake” across the U.S. Patient Hub, with approximately 400 patients enrolled to date.
- Community‑Setting Adoption – About 25 % of enrolled patients are receiving treatment in community settings, underscoring ease of administration and accessibility.
- Upcoming Durability Data – Updated durability of response data will be presented at the ASCO Annual Meeting, potentially expanding market confidence.
The company’s CEO, Helen Sabzevari, highlighted the strategic significance of PAPZIMEOS in improving patient lives and noted the momentum that could translate into expanded geographic reach and pediatric applications.
AdenoVerse® Pipeline – Focus on PRGN‑2009
Precigen continues to develop PRGN‑2009, a therapeutic candidate targeting HPV‑associated cancers. The company plans to deliver a comprehensive AdenoVerse pipeline update later in 2026. This commitment signals a continued effort to diversify its product portfolio beyond PAPZIMEOS and to capitalize on the growing market for precision medicines.
Financial Outlook & Cash‑Flow Forecast
With $56.7 million in cash and the expected influx of PAPZIMEOS revenue, Precigen anticipates reaching cash‑flow break‑even by year‑end 2026. The company’s operating model remains conservative, focusing on incremental growth while maintaining liquidity to fund R&D and commercial initiatives.
Analyst Sentiment
Finanzen.net analysts projected a Q1 2026 EPS loss of –$0.034 per share, a modest improvement over the actual –$0.02 reported. Revenue expectations were set at $20.8 million, aligning closely with the actual $23.25 million. For FY 2026, analysts forecast an average loss of –$0.046 per share and total revenue of $115.4 million versus $9.7 million the previous fiscal year, underscoring the market’s recognition of Precigen’s accelerated growth trajectory.
Conclusion
Precigen Inc. demonstrated a decisive first‑quarter performance in 2026, surpassing financial expectations and solidifying the commercial success of PAPZIMEOS™. The company’s strategic focus on the AdenoVerse® pipeline, coupled with a strong cash position and a clear path to cash‑flow break‑even, positions it well to continue delivering innovative therapies in the biotechnology sector.
